logo

PMCB

PharmaCyte Biotech·NASDAQ
--
--(--)
--
--(--)
4.83 / 10
Netural

PMCB's fundamentals score 4.8/10, indicating a balanced but not outstanding quality. Strengths include a favorable PB-ROE (-0.9610) and Cash-MV (0.1376), while concerns are raised by Net profit / Total profit (%) at 100% (possibly indicating data oddity) and a high Inventory turnover ratio (110.9994) that may distort liquidity assessment. Asset-MV (-0.5033) and Revenue-MV (0.1569) show moderate performance, and Gross profit margin (%) at 48.17% is acceptable but not exceptional. The factor-weighted score of 4.83 reflects these trade-offs, leading to a neutral fundamental stance.

Fundamental(4.83)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value0.16
Score1/3
Weight9.16%
1M Return5.20%
Inventory turnover ratio
Value111.00
Score3/3
Weight8.05%
1M Return5.26%
Gross profit margin (%)
Value48.17
Score1/3
Weight-0.71%
1M Return-0.54%
Profit-MV
Value0.44
Score3/3
Weight29.26%
1M Return12.18%
PB-ROE
Value-0.96
Score3/3
Weight21.53%
1M Return11.47%
Current assets turnover ratio
Value2.56
Score2/3
Weight1.60%
1M Return1.15%
Fixed assets turnover ratio
Value28052.73
Score3/3
Weight1.17%
1M Return0.86%
Asset-MV
Value-0.50
Score1/3
Weight16.62%
1M Return8.74%
Cash-MV
Value0.14
Score2/3
Weight13.73%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.41%
1M Return-0.30%
Is PMCB fundamentally strong?
  • PMCB scores 4.83/10 on fundamentals and holds a Fair valuation at present. Backed by its -37.94% ROE, 0.00% net margin, -0.68 P/E ratio, 0.21 P/B ratio, and -226.14% earnings growth, these metrics solidify its Netural investment rating.